200 related articles for article (PubMed ID: 22522328)
1. Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain.
Osuka S; Takano S; Watanabe S; Ishikawa E; Yamamoto T; Matsumura A
Neurol Med Chir (Tokyo); 2012; 52(4):186-93. PubMed ID: 22522328
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid for the treatment of pediatric malignant glioma.
Driever PH; Knüpfer MM; Cinatl J; Wolff JE
Klin Padiatr; 1999; 211(4):323-8. PubMed ID: 10472571
[TBL] [Abstract][Full Text] [Related]
3. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals.
Zhao Y; You W; Zheng J; Chi Y; Tang W; Du R
Clin Transl Oncol; 2016 Nov; 18(11):1123-1130. PubMed ID: 26942921
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and antiangiogenic therapy for malignant gliomas.
Takano S; Kamiyama H; Tsuboi K; Matsumura A
Brain Tumor Pathol; 2004; 21(2):69-73. PubMed ID: 15700836
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
[TBL] [Abstract][Full Text] [Related]
8. Re: angiogenesis and antiangiogenic therapy for malignant gliomas.
Kepes JJ
Brain Tumor Pathol; 2005; 22(1):51. PubMed ID: 18095105
[No Abstract] [Full Text] [Related]
9. Valproic acid inhibits angiogenesis in vitro and in vivo.
Michaelis M; Michaelis UR; Fleming I; Suhan T; Cinatl J; Blaheta RA; Hoffmann K; Kotchetkov R; Busse R; Nau H; Cinatl J
Mol Pharmacol; 2004 Mar; 65(3):520-7. PubMed ID: 14978230
[TBL] [Abstract][Full Text] [Related]
10. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
11. Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo.
Shan Z; Feng-Nian R; Jie G; Ting Z
Asian Pac J Cancer Prev; 2012; 13(8):3977-82. PubMed ID: 23098503
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Zhang YH; Yue ZJ; Zhang H; Tang GS; Wang Y; Liu JM
Eur J Pharm Biopharm; 2010 Nov; 76(3):371-5. PubMed ID: 20816959
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Gao D; Xia Q; Lv J; Zhang H
Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
[TBL] [Abstract][Full Text] [Related]
14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
15. The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway.
Liu D; Cao G; Cen Y; Liu T; Peng W; Sun J; Li X; Zhou H
Int Immunopharmacol; 2013 Oct; 17(2):237-44. PubMed ID: 23791618
[TBL] [Abstract][Full Text] [Related]
16. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
Anderson JC; Grammer JR; Wang W; Nabors LB; Henkin J; Stewart JE; Gladson CL
Cancer Biol Ther; 2007 Mar; 6(3):454-62. PubMed ID: 17384534
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
Berendsen S; Broekman M; Seute T; Snijders T; van Es C; de Vos F; Regli L; Robe P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1391-415. PubMed ID: 22668241
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients.
Li C; Chen H; Tan Q; Xie C; Zhan W; Sharma A; Sharma HS; Zhang Z
Prog Brain Res; 2020; 258():369-379. PubMed ID: 33223038
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro.
Knüpfer MM; Hernáiz-Driever P; Poppenborg H; Wolff JE; Cinatl J
Anticancer Res; 1998; 18(5A):3585-9. PubMed ID: 9858943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
